peplomycin and Carcinoma--Intraductal--Noninfiltrating

peplomycin has been researched along with Carcinoma--Intraductal--Noninfiltrating* in 1 studies

Other Studies

1 other study(ies) available for peplomycin and Carcinoma--Intraductal--Noninfiltrating

ArticleYear
[Clinical effect of Peplomycin on recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:7

    Twelve patients with recurrent breast cancer were treated with Peplomycin monotherapy. Peplomycin was given intermittently with a dose of 10 mg intramuscularly twice a week. As side effects of Peplomycin, fever elevation in 75% (9/12), malaise in 67%, nausea and vomiting in 42%, anorexia in 42%, pulmonary toxicity in 8%, and loss of hair in 8%, were observed. Out of 8 evaluable cases, CR was obtained in 1, PR in 1, NC in 3, and PD in 3 cases, respectively.

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peplomycin

1983